Immunohistochemical Method and Histopathology Judging for the Systemic Synuclein Sampling Study (S4).

Area of Science:

• Neuropathology
• Biomarker Discovery
• Neurodegenerative Diseases

Background:

• Parkinson disease (PD) diagnosis relies on clinical symptoms and requires definitive post-mortem confirmation.
• Peripheral biopsies are being investigated as potential accessible biomarkers for early PD detection.
• Immunohistochemical (IHC) detection of alpha-synuclein (Asyn) pathology is a key area of research.

Purpose of the Study:

• To evaluate the utility of IHC Asyn pathology in peripheral biopsies (skin, colon, submandibular gland) as a biomarker for Parkinson disease.
• To assess the sensitivity and specificity of candidate IHC methods and the reliability of neuropathologist scoring.
• To validate the Systemic Synuclein Sampling Study (S4) protocol for diagnosing PD.

Main Methods:

• A multi-center study (S4) involving 60 PD patients and 20 controls.
• Collection and analysis of skin, colon, and submandibular gland biopsies.
• Utilizing IHC with the 5C12 monoclonal antibody to detect Asyn pathology.
• Training and testing of neuropathologists on scoring Asyn pathology using glass slides and digital images.

Main Results:

• The 5C12 antibody method demonstrated 100% specificity in preliminary testing.
• Sensitivity varied by tissue type, with the chosen method showing 67% sensitivity in skin biopsies.
• Trained neuropathologists achieved high specificity (near 100%) and sensitivity (75-83.5%) across tissues, with slight differences between digital and glass slide readings.
• Inter-rater agreement for semiquantitative scoring was moderate (62-67%).

Conclusions:

• IHC Asyn pathology in peripheral biopsies shows potential as a biomarker for Parkinson disease.
• The 5C12 antibody and standardized neuropathologist training are crucial for reliable detection.
• Further validation is needed, particularly regarding sensitivity in skin biopsies and optimizing digital image analysis.